Month: July 2023

TORONTO, July 07, 2023 (GLOBE NEWSWIRE) — Banxa Holdings Inc. (TSXV: BNXA) (OTCQX: BNXAF) (FSE: AC00) (“Banxa” or the “Company“) announced today that the common shares of the Company will be reinstated for trading on the TSX Venture Exchange, effective Monday, July 10, 2023, in connection with the revocation of the Company’s cease trade order (the “CTO“) issued by the British Columbia Securities Commission and the Ontario Securities Commission on November 3, 2022. The CTO was issued due to the Company’s failure to file its audited financial statements, the related management’s discussion and analysis, and the related certification for the year ended June 30, 2022 (together, the “CTO Financial Statements”). The CTO Financial Statements have now been filed and are available for review by interested...

GOLDEN, Colo., July 07, 2023 (GLOBE NEWSWIRE) — Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a plant-based natural health ingredient and product company, today announced expansion plans that target natural health and wellness across a broad spectrum of products. In recent years, the therapeutic health and wellness interest in natural plant based products has exploded, given rise to increasing consumer interest and attention from the medical/scientific community. The Company plans to capitalize on this trend by expanding its focus to include Kratom and Kava and evaluating additional acquisition candidates for natural and organic based products in the natural health and wellness sector, including introduction of non-alcoholic health and energy drinks and vaping products. The Company will continue...

Not for distribution to United States newswire services or for dissemination in the United States TORONTO, July 07, 2023 (GLOBE NEWSWIRE) — BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce, further to its June 23, 2023 news release, the closing of the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”) for gross proceeds of approximately $550,050.00 from the sale of 1,833,500 units of the Company (each, a “Unit”) at a price of $0.30 per Unit (the “Issue Price”). BULGOLD issued a total of 7,366,831 Units for gross proceeds of approximately $2.21 million under the Offering. Each Unit consists of one common share of the Company (each a “Unit Share”) and one-half of one common share purchase warrant...

Several AI-Powered Features Presently Not Available in the Marketplace Are Expected to be Announced Detroit, Michigan, July 07, 2023 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc., (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that several advanced AI functions are expected to be unveiled at Thursday’s ‘Police Day’ event. RAD’s Police Day event will be held July 13 at the Company’s manufacturing facility, the ‘REX’, located in Ferndale, Michigan. Police Day is meant to showcase the RADDOG family of robots to area law enforcement personnel that may be considering adding advanced robotics to their force. RAD recently announced that it is taking pre-orders for RADDOG...

WithSecure Corporation, Press Release, 7 July 2023 at 15:00 EEST WithSecure Corporation to publish half-year report for January-June 2023 on 14 July 2023 WithSecure Corporation will publish its half-year 2023 report for January-June 2023 on Friday 14 July 2023 at approximately 08:00 EEST. WithSecure’s CEO Juhani Hintikka and CFO Tom Jansson will present the results in a webcast starting at 14:00 EEST. The webcast will be held in English and can be accessed at https://withsecure.videosync.fi/2023-07-14-wsq2ir. Questions are requested in written format in the webcast portal. Analysts following WithSecure are invited to the presentation at the company headquarters, Tammasaarenkatu 7, Helsinki, Finland. Presentation material and the webcast recording will be available on the company’s website at https://www.withsecure.com/en/about-us/investor-relations. Contact...

Maha Energy AB (publ) (“Maha” or the “Company”), announces the preliminary unaudited net production data for June 2023.Daily average production (boe/day) in 2023Assets Q1-23 Q2-23 Apr May JunPeroá cluster* 437 560 490 637 549Papa Terra cluster* 936 1,217 1,583 768 1,314Illinois Basin 233 211 217 214 202Total 1,606 1,988 2,291 1,619 2,065* Note: The information included hereunder relates only to Maha’s entitlement on Peroá and Papa Terra clusters’ production, considering its indirect participation interest on said assets. It was calculated based on the information made public by 3R Petroleum. The production from Peroá and Papa Terra clusters will not be consolidated in Maha’s financial reporting. Maha has an indirect working interest of 15% in the Peroá cluster and 9.375% in the Papa Terra cluster, with 3R Petroleum...

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder (ADHD) in adults. FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol (150 mg or 300 mg) or placebo for 6 weeks. The primary endpoint will be change in the Adult ADHD Investigator...

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced late-breaking new clinical data demonstrating that KidneyIntelX in vitro prognostic use was associated with post-test actions that led to sustained improvements in both type 2 diabetes and chronic kidney disease health through 12 months. The results are from the evaluation of 2,317 patients being followed in a large real-world evidence (RWE) study in New York City. The twelve-month outcome data were presented at the American Diabetes Association (ADA) 83rd...